Journal
JCI INSIGHT
Volume 6, Issue 14, Pages -Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.146314
Keywords
-
Categories
Funding
- NIH [R01 CA197916, R01 CA245323, U01 CA224193]
- University of Pennsylvania Molecular Pathology and Imaging Core of the Center for Molecular Studies in Digestive and Liver Diseases grant [P30 DK050306]
- Stand Up to Cancer Innovative Research Grant [SU2CAACR-IRG 13-17]
- Cancer Research Institute Irvington Fellowship
- Robert L. Fine Cancer Research Foundation
Ask authors/readers for more resources
Agonist CD40 antibodies in combination with chemotherapy can lead to systemic cytokine release, liver transaminase elevations, and chemotherapy-induced hepatotoxicity. However, neutralization of TNF can mitigate liver sensitivity to toxicity induced by anti-CD40, without affecting antitumor efficacy.
Agonist CD40 antibodies are under clinical development in combination with chemotherapy as an approach to prime for antitumor T cell immunity. However, treatment with anti-CD40 is commonly accompanied by both systemic cytokine release and liver transaminase elevations, which together account for the most common dose-limiting toxicities. Moreover. anti-CD40 treatment increases the potential for chemotherapy-induced hepatotoxicity. Here, we report a mechanistic link between cytokine release and hepatotoxicity induced by anti-CD40 when combined with chemotherapy and showthat toxicity can be suppressed without impairing therapeutic efficacy. We demonstrate in mice and humans that anti-CD40 triggers transient hepatotoxicity marked by increased serum transamina se levels. In doing so, anti-CD40 sensitizes the liver to drug-induced toxicity. Unexpectedly, this biology is not blocked by the depletion of multiple myeloid cell subsets, including macrophages, inflammatory monocytes, and granulocytes. Transcriptional profiling of the liver after anti-CD40 revealed activation of multiple cytokine pathways including TNF and IL-6. Neutralization of TNF, but not IL-6, prevented sensitization of the liver to hepatotoxicity induced with anti-CD40 in combination with chemotherapy without impacting antitumor efficacy. Our findings reveal a clinically feasible approach to mitigate toxicity without impairing efficacy in the use of agonist CD40 antibodies for cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available